Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-123 pharmacokinetics in Japanese healthy males
NCT04155567Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium phenylacetate + sodium benzoate, sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration at 48 hours and 1 more. Started Nov 2019; status: completed.
02
Drugs
sodium phenylacetate + sodium benzoate
Beyond the preview
Go deeper on NCT04155567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155567.